These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15726532)

  • 1. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of chemotherapy dose intensity in lung cancer.
    Crawford J
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):25-31. PubMed ID: 15726536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dose density and dose intensity in the treatment of breast cancer].
    Saintigny P; Assouad S; Gligorov J; Selle F; Roché H; Breau JL; Morère JF; Lotz JP
    Bull Cancer; 2004 Dec; 91 Suppl 4():S244-53. PubMed ID: 15899616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives in the treatment of colorectal cancer.
    Ozer H; Diasio RB
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):14-8. PubMed ID: 15726534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy for breast cancer.
    Hennessy BT; Pusztai L
    Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
    J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
    Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of dose-dense chemotherapy for breast cancer.
    Seidman AD
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():78-83. PubMed ID: 16273358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
    Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
    Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: implications for optimal postoperative adjuvant chemotherapy.
    Uchida J; Okabe H; Nakano K; Fujioka A; Saito H; Sugimoto Y; Oka T; Fukushima M
    Oncol Rep; 2007 Aug; 18(2):313-9. PubMed ID: 17611650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
    Kuo SH; Lien HC; You SL; Lu YS; Lin CH; Chen TZ; Huang CS
    Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.